Drugs for Gastrointestinal Diseases Practice Questions

Q: Which of the following proton pump inhibitors has enzyme inhibitory activity?

Omeprazole. **Explanation:** **1. Why Omeprazole is the Correct Answer:** Omeprazole is a potent inhibitor of the hepatic microsomal enzyme system, specifically **CYP2C19** and **CYP3A4**. By inhibiting these enzymes, it reduces the metabolism of several drugs, leading to increased plasma concentrations and potential toxicity. This is a classic pharmacological property of the first-generation PPI, Omeprazole, which distinguishes it from newer agents in the class. **2. Why the Other Options are Incorrect:** * **Pantoprazole:** Known for having the **least potential** for drug-drug interactions. It has lower affinity for cytochrome P450 enzymes, making it the preferred PPI for patients on multiple medications (polypharmacy). * **Rabeprazole:** Primarily metabolized via a non-enzymatic pathway (reduction) with minor CYP involvement, resulting in minimal enzyme inhibition. * **Lansoprazole:** While it is metabolized by CYP enzymes, its inhibitory effect on the metabolism of other drugs is clinically insignificant compared to Omeprazole. **3. High-Yield Clinical Pearls for NEET-PG:** * **The Clopidogrel Interaction:** This is the most high-yield clinical application. Clopidogrel is a prodrug activated by **CYP2C19**. Because Omeprazole inhibits this enzyme, it prevents the activation of Clopidogrel, potentially increasing the risk of cardiovascular events (thrombosis). * **Other Interactions:** Omeprazole increases the half-life of **Warfarin, Phenytoin, and Diazepam**. * **Mechanism of Action:** All PPIs are prodrugs that irreversibly inhibit the **H+/K+ ATPase pump** (proton pump) in gastric parietal cells. * **Fastest Acting PPI:** Rabeprazole is often cited as having the fastest onset of action among the group.

Q: What is the drug of choice for late cisplatin-induced vomiting?

Aprepitant. **Explanation:** Cisplatin-induced emesis occurs in two distinct phases: **Acute** (within 24 hours) and **Delayed/Late** (24–72 hours). Understanding the neurotransmitters involved is key to selecting the correct therapy. 1. **Why Aprepitant is correct:** The delayed phase of vomiting is primarily mediated by **Substance P** acting on **Neurokinin-1 (NK1) receptors** in the solitary tract nucleus. **Aprepitant** is a selective NK1 receptor antagonist. It is specifically indicated for the prevention of delayed emesis because 5-HT3 antagonists (like Granisetron) lose their efficacy after the first 24 hours. 2. **Why other options are incorrect:** * **Granisetron:** This is a 5-HT3 receptor antagonist. While it is the drug of choice for **acute** cisplatin-induced vomiting, it is significantly less effective for the delayed phase. * **Dexamethasone:** While often used as an adjuvant to enhance the efficacy of both 5-HT3 and NK1 antagonists, it is not the primary drug of choice for the late phase when used alone. * **Omeprazole:** This is a Proton Pump Inhibitor (PPI) used for peptic ulcers and GERD; it has no anti-emetic properties. **High-Yield Clinical Pearls for NEET-PG:** * **Acute Emesis ( 24h):** Mediated by Substance P (NK1). DOC: **Aprepitant/Rolapitant.** * **Anticipatory Emesis:** Triggered by psychological factors/sights/smells. DOC: **Lorazepam (Benzodiazepines).** * **Palonosetron:** A second-generation 5-HT3 antagonist with a long half-life that has some efficacy in both acute and delayed phases.

Q: A patient is diagnosed with Zollinger-Ellison syndrome. Which of the following would be the most appropriate pharmacotherapy?

Omeprazole. **Zollinger-Ellison Syndrome (ZES)** is characterized by a gastrin-secreting tumor (gastrinoma), usually located in the pancreas or duodenum. This leads to massive hypersecretion of gastric acid, resulting in severe, recurrent peptic ulcers and diarrhea. **1. Why Omeprazole is correct:** Proton Pump Inhibitors (PPIs) like **Omeprazole** are the drugs of choice for ZES [1]. They irreversibly inhibit the $H^+/K^+$-ATPase pump in gastric parietal cells, which is the final common pathway of acid secretion [1]. Because PPIs can achieve near-total suppression of acid regardless of the stimulus (gastrin, histamine, or acetylcholine), they are effective even against the extreme hypergastrinemia seen in ZES [1]. High doses are typically required initially. **2. Why the other options are incorrect:** * **Famotidine:** This is an $H_2$ receptor antagonist. While it reduces acid, it is significantly less potent than PPIs and cannot adequately control the massive acid output triggered by gastrinomas. * **Fluorouracil (5-FU):** This is a cytotoxic antimetabolite used in cancer chemotherapy. While ZES involves a tumor, the primary management of symptoms and mucosal damage relies on acid suppression, not 5-FU. * **Erythropoietin:** This is a hormone that stimulates red blood cell production; it has no role in acid-peptic disease. **Clinical Pearls for NEET-PG:** * **Diagnosis:** ZES is suspected when fasting serum gastrin levels are >1000 pg/mL. The **Secretin Stimulation Test** is the most specific provocative test (Secretin causes a paradoxical *increase* in gastrin in ZES patients). * **MEN-1 Association:** Approximately 25% of ZES cases occur as part of Multiple Endocrine Menaplasia Type 1 (3Ps: Parathyroid, Pancreas, Pituitary). * **Drug of Choice:** PPIs are the DOC for ZES, NSAID-induced ulcers, and H. pylori-associated peptic ulcer disease [1].

Q: All of the following are effective against cytotoxic drug-induced emesis except?

Hyoscine. **Explanation:** The management of chemotherapy-induced nausea and vomiting (CINV) targets specific neurotransmitter pathways in the **Chemoreceptor Trigger Zone (CTZ)** and the **Vagal afferents** in the GI tract. **Why Hyoscine is the correct answer:** Hyoscine (Scopolamine) is an anticholinergic drug that primarily acts on the vestibular system (M1 receptors). It is the drug of choice for **motion sickness** and vertigo but has **no significant efficacy** against cytotoxic drug-induced emesis. CINV is primarily mediated by serotonin (5-HT3), dopamine (D2), and substance P (NK1), rather than the vestibular-cholinergic pathway. **Analysis of other options:** * **Ondansetron:** A 5-HT3 receptor antagonist. It is the first-line agent for preventing acute CINV by blocking serotonin receptors on vagal afferents and the CTZ. * **Dexamethasone:** A corticosteroid that is highly effective against CINV, especially when used in combination with 5-HT3 antagonists. Its mechanism involves reducing peritumoral inflammation and prostaglandin synthesis. * **Metoclopramide:** A D2 receptor antagonist. In high doses, it also possesses 5-HT3 antagonistic activity, making it effective against cisplatin-induced emesis (though now largely superseded by newer agents). **High-Yield Clinical Pearls for NEET-PG:** 1. **Drug of choice for Motion Sickness:** Hyoscine (administered as a transdermal patch behind the ear). 2. **Drug of choice for CINV (Acute):** Ondansetron (5-HT3 antagonist). 3. **Drug of choice for Delayed CINV:** Aprepitant (NK1 receptor antagonist). 4. **Drug of choice for Morning Sickness (Pregnancy):** Doxylamine + Pyridoxine. 5. **Metoclopramide Side Effect:** Can cause Extrapyramidal Symptoms (EPS) like acute dystonia due to central D2 blockade.

Q: What is the antibiotic of choice in a cirrhotic patient to prevent hepatic encephalopathy?

Rifaximin. ### Explanation **Correct Answer: D. Rifaximin** **Mechanism and Rationale:** Hepatic encephalopathy (HE) is primarily caused by the accumulation of neurotoxic ammonia, produced by urea-splitting bacteria in the gut. **Rifaximin** is a semi-synthetic, non-absorbable derivative of Rifampin. It acts locally in the gastrointestinal tract to inhibit bacterial RNA synthesis, thereby reducing the population of ammonia-producing enteric flora. Because it has minimal systemic absorption (<0.4%), it offers a superior safety profile with fewer systemic side effects, making it the current **drug of choice** for the prevention of recurrent HE episodes. **Analysis of Incorrect Options:** * **A. Neomycin:** Historically used to decrease ammonia-producing bacteria. However, it is no longer the first choice due to risks of **ototoxicity and nephrotoxicity**, even with minimal absorption, especially in patients with renal impairment. * **B. Ampicillin:** While it can alter gut flora, it is not specific for HE and carries a high risk of developing antibiotic resistance and *Clostridioides difficile* infection. * **C. Metronidazole:** Effective against anaerobes that produce ammonia, but long-term use is limited by the significant risk of **peripheral neuropathy**. **NEET-PG High-Yield Pearls:** * **First-line treatment for acute HE:** Lactulose (a non-absorbable disaccharide that traps ammonia as ammonium ions [$NH_4^+$] by acidifying the colon). * **Rifaximin's Role:** Primarily used as an add-on therapy to Lactulose for the prevention of recurrence. * **Mechanism of Rifaximin:** Binds to the beta-subunit of bacterial DNA-dependent RNA polymerase. * **Clinical Advantage:** Unlike Neomycin, Rifaximin does not require dosage adjustment in renal failure and has a lower potential for drug-drug interactions.

Q: What is not a rationale for sucralfate therapy in peptic ulcers?

It has an acid neutralizing action.. **Explanation:** Sucralfate is a complex of **aluminum hydroxide and sulfated sucrose**. Its primary mechanism of action is physical rather than chemical, making it a "cytoprotective" agent rather than an antacid. **1. Why Option A is the correct answer:** Sucralfate **does not have a significant acid-neutralizing capacity**. Unlike antacids (like Magnesium or Aluminum hydroxide), sucralfate requires an **acidic environment (pH < 4)** to be activated. In acidic medium, it polymerizes into a sticky, viscous paste that binds selectively to the base of the ulcer crater. Therefore, claiming it neutralizes acid is pharmacologically incorrect. **2. Why the other options are incorrect (Mechanisms of Sucralfate):** * **Option B:** The negatively charged sucrose sulfate binds to positively charged proteins (albumin, fibrinogen) in the ulcer base, forming a physical barrier that **prevents degradation by pepsin** and bile salts. * **Option C:** Sucralfate binds to **Epidermal Growth Factor (EGF)** and fibroblast growth factor, concentrating them at the ulcer site to promote mucosal regeneration and healing. * **Option D:** It stimulates the local release of **Prostaglandins (PGE2 and PGI2)** and nitric oxide, which increases mucosal blood flow and bicarbonate secretion. **High-Yield Clinical Pearls for NEET-PG:** * **Administration:** It must be taken on an **empty stomach** (1 hour before meals). * **Drug Interactions:** Since it requires low pH for activation, it should **not** be given simultaneously with **Antacids, H2 blockers, or PPIs** (maintain a gap of 30–60 mins). * **Side Effects:** The most common side effect is **constipation** (due to the aluminum content). * **Hypophosphatemia:** It can bind to dietary phosphates, potentially leading to low phosphate levels in chronic use.

Q: Which of the following prokinetic drugs has been implicated in causing serious ventricular arrhythmias, particularly in patients concurrently receiving erythromycin or ketoconazole?

Cisapride. **Explanation:** **Cisapride** is the correct answer because it is a substituted benzamide prokinetic that acts as a potent **5-HT₄ receptor agonist**. Its clinical use has been severely restricted or withdrawn in many countries due to its potential to cause **QT interval prolongation** and life-threatening ventricular arrhythmias, specifically **Torsades de Pointes**. The underlying mechanism involves the blockade of **HERG (human ether-a-go-go-related gene) potassium channels** in the heart, which delays repolarization. Cisapride is metabolized primarily by the **CYP3A4** enzyme. Therefore, concurrent administration of CYP3A4 inhibitors like **erythromycin** (macrolide) or **ketoconazole** (azole antifungal) leads to toxic plasma levels of Cisapride, significantly increasing the risk of fatal arrhythmias. **Analysis of Incorrect Options:** * **Domperidone (A):** While it can cause QT prolongation at high doses, it is a peripheral D₂ antagonist and does not carry the same high-risk profile for drug-drug interactions as Cisapride. * **Mosapride (C):** A newer 5-HT₄ agonist that is considered safer because it lacks significant affinity for the HERG potassium channels, thus carrying a lower risk of arrhythmias. * **Metoclopramide (D):** A D₂ antagonist and 5-HT₄ agonist. Its primary side effects are extrapyramidal (dystonias, Parkinsonism) due to central D₂ blockade, not cardiac arrhythmias. **High-Yield Pearls for NEET-PG:** * **Drug of Choice (DOC):** Metoclopramide is often the DOC for diabetic gastroparesis but is contraindicated in pheochromocytoma. * **Prucalopride:** A highly selective 5-HT₄ agonist used for chronic constipation with a superior cardiac safety profile. * **Erythromycin:** Acts as a prokinetic by stimulating **motilin receptors**, but its use is limited by tachyphylaxis.

Q: Which of the following statements regarding H2 receptor antagonists is FALSE?

They consistently lower the esophageal sphincter pressure.. **Explanation:** **Why Option C is the Correct (False) Statement:** H2 receptor antagonists (H2RAs) like Ranitidine and Famotidine primarily act on the parietal cells of the stomach. They have **no significant effect on the Lower Esophageal Sphincter (LES) pressure**. In clinical practice, drugs that decrease LES pressure (like Calcium Channel Blockers or Nitrates) can actually worsen Gastroesophageal Reflux Disease (GERD). Since H2RAs are used to treat GERD, they would be counterproductive if they lowered LES pressure. **Analysis of Other Options:** * **Option A:** H2RAs are competitive antagonists. They produce a **dose-dependent inhibition** of gastric acid secretion, especially effective against basal (nocturnal) acid secretion stimulated by histamine. * **Option B:** These drugs effectively reduce both the **total volume** of gastric juice and the **concentration of Hydrogen ions** (acidity). They also indirectly reduce pepsin secretion. * **Option D:** Intrinsic factor is secreted by the same parietal cells that secrete HCl. While H2RAs do reduce the secretion of intrinsic factor, this is rarely clinically significant in short-term use because the body has large stores of Vitamin B12. **NEET-PG High-Yield Pearls:** * **Cimetidine Specifics:** It is a potent **P450 enzyme inhibitor** and has **anti-androgenic effects** (can cause gynecomastia and galactorrhea). * **Drug of Choice:** Proton Pump Inhibitors (PPIs) have largely replaced H2RAs for PUD and GERD due to superior efficacy and longer duration of action. * **Tolerance:** Unlike PPIs, H2RAs can exhibit **tachyphylaxis** (rapidly diminishing response) within 3-7 days of starting therapy.

Question 1

Which of the following proton pump inhibitors has enzyme inhibitory activity?

Accepted Answer

Omeprazole

Answer

Rabeprazole

Answer

Lansoprazole

Answer

Pantoprazole

Question 2

What is the drug of choice for late cisplatin-induced vomiting?

Accepted Answer

Aprepitant

Answer

Omeprazole

Answer

Granisetron

Answer

Dexamethasone

Question 3

Which of the following pharmacologic agents is not used in the management of Crohn's disease?

Accepted Answer

Ustekinumab

Answer

Infliximab

Answer

Adalimumab

Answer

Natalizumab

Question 4

Which of the following drugs is NOT used for paralytic ileus following bowel resection surgery?

Accepted Answer

Naloxone

Answer

Alvinopam

Answer

Dihydroergotamine

Answer

Methylnaltrexone

Question 5

A patient is diagnosed with Zollinger-Ellison syndrome. Which of the following would be the most appropriate pharmacotherapy?

Accepted Answer

Omeprazole

Answer

Erythropoietin

Answer

Famotidine

Answer

Fluorouracil

Question 6

All of the following are effective against cytotoxic drug-induced emesis except?

Accepted Answer

Hyoscine

Answer

Dexamethasone

Answer

Metoclopramide

Answer

Ondansetron

Question 7

What is the antibiotic of choice in a cirrhotic patient to prevent hepatic encephalopathy?

Accepted Answer

Rifaximin

Answer

Neomycin

Answer

Ampicillin

Answer

Metronidazole

Question 8

What is not a rationale for sucralfate therapy in peptic ulcers?

Accepted Answer

It has an acid neutralizing action.

Answer

It inhibits pepsin mediated protein hydrolysis.

Answer

It stimulates the production of epidermal growth factor.

Answer

It stimulates prostaglandin synthesis.

Question 9

Which of the following prokinetic drugs has been implicated in causing serious ventricular arrhythmias, particularly in patients concurrently receiving erythromycin or ketoconazole?

Accepted Answer

Cisapride

Answer

Domperidone

Answer

Mosapride

Answer

Metoclopramide

Question 10

Which of the following statements regarding H2 receptor antagonists is FALSE?

Accepted Answer

They consistently lower the esophageal sphincter pressure.

Answer

They produce a dose-dependent inhibition of gastric acid secretion elicited by histamine.

Answer

They reduce the volume as well as H+ ion concentration of gastric juice.

Answer

They also reduce the secretion of intrinsic factor.

Drugs for Gastrointestinal Diseases — MCQs

Drugs for Gastrointestinal Diseases — MCQs

On this page

Practice by Chapter

Want unlimited practice?